Detralex® has venotonic and angioprotective properties.
The drug reduces the extensibility of veins and venous congestion, reduces the permeability of capillaries and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to venous hemodynamics.
The statistically significant dose-dependent effect of Detralex® was demonstrated for the following venous plethysmographic parameters: venous capacity, venous extensibility, time of venous emptying. The optimal dose / effect ratio is observed when taking 2 tablets.
Detralex® improves venous tone: venous occlusion plethysmography has been shown to decrease venous emptying time. In patients with signs of severe microcirculatory dysfunction (statistically significant), compared with placebo, an increase in capillary resistance, evaluated by angiostereometry, after therapy with Detralex®, is noted.
The therapeutic efficacy of Detralex® has been proven in the treatment of chronic lower extremity vein diseases, as well as in the treatment of hemorrhoids.
The main excretion of the drug occurs with feces. With urine, on average, about 14% of the accepted amount of the drug is excreted.
T1 / 2 is 11 hours.
The drug undergoes active metabolism, as evidenced by the presence of phenolic acids in the urine.
Symptomatic therapy of venous-lymphatic insufficiency, feeling of heaviness in the legs, pain, Morning leg fatigue, cramps, trophic disorders, symptomatic therapy of exacerbation of hemorrhoids.
Hypersensitivity to the components of the drug.
Pregnancy and lactation
Animal experiments have not revealed teratogenic effects.
To date, there have been no reports of any side effects when using the drug in pregnant women.
Due to a lack of data regarding the excretion of the drug in breast milk, lactation is not recommended for women.
With exacerbation of hemorrhoids, the use of this drug does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the recommended time frame. In the event that the symptoms do not disappear after a short therapy, a proctological examination should be carried out and the ongoing therapy should be reviewed.
In the presence of impaired venous circulation, the maximum treatment effect is ensured by a combination with a healthy, well-balanced lifestyle, in which it is advisable to avoid long exposure to the sun, reduce body weight, take walks and, in some cases, wear special socks that improve blood circulation.
Effect on the ability to drive vehicles and control mechanisms
The drug does not affect the ability to drive vehicles and perform work requiring a high speed of psychomotor reactions.
1 tablet contains:
Active ingredients: purified micronized flavonoid fraction 500 mg (including diosmin (90%) 450 mg, flavonoids expressed as hesperidin (10%) 50 mg)
Excipients: gelatin gelatin , microcrystalline cellulose, sodium starch glycolate, talc, glycerol, macrogol 6000, hydroxypropyl methylcellulose, iron oxide yellow (E172), iron oxide red (E172), titanium dioxide (E171), sodium lauryl sulfate.
Dosage and administration of
The drug is taken orally.
The recommended dose is 2 tablets per day, 1 tablet in the middle of the day and 1 tablet in the evening during meals.
During an exacerbation of hemorrhoids - 6 tablets per day for 4 days, then 4 tablets per day for the next 3 days.
From the central nervous system: rarely - dizziness, headache, general malaise.
From the gastrointestinal tract: often - diarrhea, dyspepsia, nausea, vomiting infrequently - colitis.
From the skin: rarely - rash, itching, urticaria of unspecified frequency - isolated swelling of the face, lips, eyelids. In exceptional cases, angioedema.
Adult doctor, Pregnant II and III trimester doctor, For women p6roduct5 lkp Adult doctor, Pregnant doctor
Indications srdlkr1, Urinary tract infections, Urinary tract infections, Pharyngitis, Osteomyelitis, Tonsillitis, Osteomyelitis, Skin infections, Bronchitis, Sinusitis, Cholecystitis, Periodontitis, Otitis Patients eye, Trophic ulcers, Hemorrhoids